Bellone M - Search Results

1

Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.

Bellone M, Mondino A, Corti A. Bellone M, et al. Trends Immunol. 2008 May;29(5):235-41. doi: 10.1016/j.it.2008.02.003. Epub 2008 Mar 28. Trends Immunol. 2008. PMID: 18375183 Review.

2

Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.

Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P. Moro M, et al. Among authors: bellone m. Cancer Res. 1999 Jun 1;59(11):2650-6. Cancer Res. 1999. PMID: 10363988

3

Cancer immunotherapy: synthetic and natural peptides in the balance.

Bellone M, Iezzi G, Imro MA, Protti MP. Bellone M, et al. Immunol Today. 1999 Oct;20(10):457-62. doi: 10.1016/s0167-5699(99)01503-0. Immunol Today. 1999. PMID: 10500293 Review.

4

Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.

Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Mondino A, Bellone M. Camporeale A, et al. Among authors: bellone m. Cancer Res. 2003 Jul 1;63(13):3688-94. Cancer Res. 2003. PMID: 12839960

5

Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.

Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Sacchi A, et al. Among authors: bellone m. Cancer Res. 2004 Oct 1;64(19):7150-5. doi: 10.1158/0008-5472.CAN-04-1445. Cancer Res. 2004. PMID: 15466213

6

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.

Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M. Degl'Innocenti E, et al. Among authors: bellone m. Eur J Immunol. 2005 Jan;35(1):66-75. doi: 10.1002/eji.200425531. Eur J Immunol. 2005. PMID: 15597325 Free article.

7

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration.

Casati A, Zimmermann VS, Benigni F, Bertilaccio MT, Bellone M, Mondino A. Casati A, et al. Among authors: bellone m. J Immunol. 2005 Mar 15;174(6):3317-25. doi: 10.4049/jimmunol.174.6.3317. J Immunol. 2005. PMID: 15749863

8

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, Greenberg NM, Corti A, Bellone M. Bertilaccio MT, et al. Among authors: bellone m. Prostate. 2008 Jul 1;68(10):1105-15. doi: 10.1002/pros.20775. Prostate. 2008. PMID: 18437689

9

Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.

Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A. Gasparri AM, et al. Among authors: bellone m. Mol Cancer Ther. 2008 Dec;7(12):3859-66. doi: 10.1158/1535-7163.MCT-08-0538. Mol Cancer Ther. 2008. PMID: 19074858

10

Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors.

Hess Michelini R, Freschi M, Manzo T, Jachetti E, Degl'Innocenti E, Grioni M, Basso V, Bonini C, Simpson E, Mondino A, Bellone M. Hess Michelini R, et al. Among authors: bellone m. Cancer Res. 2010 May 1;70(9):3505-14. doi: 10.1158/0008-5472.CAN-09-4253. Epub 2010 Apr 13. Cancer Res. 2010. PMID: 20388780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters